EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Rabies - Pipeline Review, H1 2015

  • ID: 3266294
  • Report
  • April 2015
  • 80 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Celltrion, Inc.
  • Humabs BioMed SA
  • Kamada Ltd.
  • NanoViricides, Inc.
  • PaxVax
  • Sanofi
  • MORE
Rabies - Pipeline Review, H1 2015

Summary

This, ‘Rabies - Pipeline Review, H1 2015’, provides an overview of the Rabies’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rabies
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rabies and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rabies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rabies pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rabies
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Celltrion, Inc.
  • Humabs BioMed SA
  • Kamada Ltd.
  • NanoViricides, Inc.
  • PaxVax
  • Sanofi
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Rabies Overview
Therapeutics Development
Pipeline Products for Rabies - Overview
Pipeline Products for Rabies - Comparative Analysis
Rabies - Therapeutics under Development by Companies
Rabies - Therapeutics under Investigation by Universities/Institutes
Rabies - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Rabies - Products under Development by Companies
Rabies - Products under Investigation by Universities/Institutes
Rabies - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co., Ltd
Celltrion, Inc.
CureVac GmbH
Humabs BioMed SA
Kaketsuken K.K.
Kamada Ltd.
Medicago Inc.
Molecular Targeting Technologies, Inc.
NanoViricides, Inc.
Novavax, Inc.
PaxVax
Prosetta Antiviral Inc.
Sanofi
Serum Institute of India Limited
Sinovac Biotech Ltd.
Trellis Bioscience, Inc.
VBI Vaccines Inc.
Zydus Cadila Healthcare Limited
Rabies - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CTP-19 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CV-7201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CV-8102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ebola + rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
human rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KD-357 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Rabies - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for Rabies - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PAV-866 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RabiCide-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies immune globulin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies virus like particle vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rabimabs - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SII RMab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SO-57 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SOJB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VerorabVax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rabies - Recent Pipeline Updates
Rabies - Dormant Projects
Rabies - Product Development Milestones
Featured News & Press Releases
Mar 04, 2014: Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies
Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel
Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America
May 01, 2007: Kamada Obtains FDA Approval to Commence Phase II and III Clinical Trials For Its KamRAB Anti-rabies Passive Immunization Product
Sep 18, 2003: Molecular Targeting Technologies, Inc. Forms Partnership With North China Pharmaceutical Company
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Rabies, H1 2015
Number of Products under Development for Rabies - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Rabies - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015
Rabies - Pipeline by Celltrion, Inc., H1 2015
Rabies - Pipeline by CureVac GmbH, H1 2015
Rabies - Pipeline by Humabs BioMed SA, H1 2015
Rabies - Pipeline by Kaketsuken K.K., H1 2015
Rabies - Pipeline by Kamada Ltd., H1 2015
Rabies - Pipeline by Medicago Inc., H1 2015
Rabies - Pipeline by Molecular Targeting Technologies, Inc., H1 2015
Rabies - Pipeline by NanoViricides, Inc., H1 2015
Rabies - Pipeline by Novavax, Inc., H1 2015
Rabies - Pipeline by PaxVax, H1 2015
Rabies - Pipeline by Prosetta Antiviral Inc., H1 2015
Rabies - Pipeline by Sanofi, H1 2015
Rabies - Pipeline by Serum Institute of India Limited, H1 2015
Rabies - Pipeline by Sinovac Biotech Ltd., H1 2015
Rabies - Pipeline by Trellis Bioscience, Inc., H1 2015
Rabies - Pipeline by VBI Vaccines Inc., H1 2015
Rabies - Pipeline by Zydus Cadila Healthcare Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Rabies Therapeutics - Recent Pipeline Updates, H1 2015
Rabies - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Rabies, H1 2015
Number of Products under Development for Rabies - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
Beijing Minhai Biotechnology Co., Ltd
Celltrion, Inc.
CureVac GmbH
Humabs BioMed SA
Kaketsuken K.K.
Kamada Ltd.
Medicago Inc.
Molecular Targeting Technologies, Inc.
NanoViricides, Inc.
Novavax, Inc.
PaxVax
Prosetta Antiviral Inc.
Sanofi
Serum Institute of India Limited
Sinovac Biotech Ltd.
Trellis Bioscience, Inc.
VBI Vaccines Inc.
Zydus Cadila Healthcare Limited
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll